Ahead of Print

Síndrome de Smiths-Magenis: Um Desafio Terapêutico
Smiths-Magenis Syndrome: A Therapeutic Challenge

Main Article Content

Beatriz Pedreira - Corresponding Author
Ana Cristina Aveiro

Abstract

Smith-Magenis syndrome is a rare disease characterized by developmental delay, behavioral changes and sleep problems secondary to circadian rhythm deregulation of melatonin. With growth there is a progressive worsening of sleep problems and violent behaviors.
This is a case of a child with Smith-Magenis syndrome with severe behavioral and sleeping problems in which the association of a ?-blocker during the day with melatonin of prolonged release at night achieved a satisfactory control of symptomatology. Although the literature available suggests acebutolol (?-1 selective blocker), propranolol (?-blocker non-selective) was used given the broad availability and vast experience of use in Portugal. The scientific literature available on pharmacological approaches in Smith-Magenis syndrome is scarce even regarding the prescription of ?-blockers. No article could be found concerning propranolol use in the particular case of this syndrome.

Keywords: Adrenergic beta-Antagonists; Child; Circadian Rhythm; Melatonin; Propranolol; Sleep Wake Disorders/ drug therapy; Smith-Magenis Syndrome/drug therapy

Article Details

1.
Pedreira B, Aveiro AC. Smiths-Magenis Syndrome: A Therapeutic Challenge. Gaz Med [Internet]. 2025 Apr. 7 [cited 2025 Apr. 19];1(1). Available from: https://gazetamedica.pt/index.php/gazeta/article/view/872
Section
CLINICAL CASE